The outlook of companies tied to Viagra's past presents a intricate investment scenario . While the initial success generated substantial profits , generic copies have significantly diminished revenue. Investing in associated pharmaceutical businesses now requires a discerning assessment of patent protection , evolving patient trends , and the pote